The startup develops therapeutic systems and pharmaceuticals specifically for patients with refractory neuro-oncological and degenerative brain diseases. By targeting serious conditions such as brain cancer, the company aims to enhance the quality of life for affected individuals through effective treatment options.
Funding
$28.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional chemotherapy for brain cancer and neurodegenerative diseases often lacks specificity, leading to significant off-target toxicity and limited efficacy due to the blood-brain barrier. Therapeutic antibodies, while target-specific, have limited potency and poor penetration across the blood-brain barrier, hindering effective treatment of these conditions.
Solution
AimedBio is a preclinical-stage biotechnology company developing antibody-drug conjugates (ADCs) and bispecific antibodies to target and treat refractory neuro-oncological and degenerative brain diseases. The company leverages a patient-derived cell-based antibody discovery technology, multi-omics platform, and translational research expertise to create innovative therapies. AimedBio's ADC technology combines the specificity of antibodies with potent toxin payloads, delivering targeted therapy directly to cancer cells while minimizing harm to healthy tissue. The company is also developing a BBB-crossing platform to enhance the penetration of therapeutic antibodies into the brain, and a brain immune modulation platform to restore brain immune homeostasis.
Target Audience
The primary target audience includes patients with refractory neuro-oncological and neurodegenerative diseases, as well as clinicians and researchers seeking more effective and targeted therapies for these conditions.
Features
- Proprietary patient-derived cell (PDC)-based antibody panning method for screening antibodies that specifically recognize and bind to target conformations.
- ADC platform with proprietary linker-payloads (AIMEDuoca™ and AIMEDecan™) demonstrating higher sensitivity to brain tumors and brain metastasis tumors.
- BBB-crossing platform that improves penetration of therapeutic antibodies by 20-fold, validated in a proprietary 3D BBB model.
- Brain immune modulation platform that targets key factors causing imbalance in brain immune homeostasis.
- Multi-omics platform for target selection and biomarker discovery through genomics, transcriptomics, and other data analysis.
- Patient-derived model (PDC/PDX) platform with over 152 brain tumor PDX models for relevant drug efficacy assessment.
- 3D tumor organoid assay platform for precise and accurate clinical outcome prediction.